Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2019

Oct 15, 2019

SELL
$120.61 - $148.29 $3,618 - $4,448
-30 Closed
0 $0
Q4 2018

Jan 30, 2019

SELL
$107.01 - $175.15 $107 - $175
-1 Reduced 3.23%
30 $4,000
Q3 2018

Nov 01, 2018

BUY
$152.62 - $189.66 $4,731 - $5,879
31 New
31 $5,000

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $22.7B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track First Personal Financial Services Portfolio

Follow First Personal Financial Services and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Personal Financial Services, based on Form 13F filings with the SEC.

News

Stay updated on First Personal Financial Services with notifications on news.